These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1074 related articles for article (PubMed ID: 9537453)

  • 21. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
    Yedibela S; Schuppan D; Müller V; Schellerer V; Tannapfel A; Hohenberger W; Meyer T
    Liver Int; 2005 Aug; 25(4):717-22. PubMed ID: 15998420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):213-9. PubMed ID: 15908318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
    N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.
    Wartelle-Bladou C; Arpurt JP; Renou C; Pariente A; Pillon D; Nalet B; Picon M; Glibert A; Chousterman M; Grasset D; Morin T; Bernard P; Fischer D; Ramdani M; Lagier E; Rotily M;
    Gastroenterol Clin Biol; 2006 Apr; 30(4):525-32. PubMed ID: 16733374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ; Chan CY; Lu RH; Wu JC; Lee SD
    J Interferon Cytokine Res; 1995 Jul; 15(7):611-6. PubMed ID: 7553231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
    Portal I; Bourlière M; Halfon P; De Lédinghen V; Couzigou P; Bernard PH; Blanc F; Caroli-Bosc F; Arpurt JP; Vetter D; Mathieu-Chandelier C; Chazouillères O; Thiefin G; Pol S; Sogni P; Abergel A; Bailly F; Picon M; Debonne JM; Zamora C; Alleman I; Moreau X; Doll F; Eugène C; Ducloux S; Larrey D; Ouzan D; Grimaud JC; Gouvernet J; Botti G; Gérolami V; Khiri H; Gérolami A; Gauthier AP; Botta-Fridlund D
    J Viral Hepat; 2003 May; 10(3):215-23. PubMed ID: 12753341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
    Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
    J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
    Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C
    J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.
    Melian EB; Plosker GL
    Drugs; 2001; 61(11):1661-91. PubMed ID: 11577799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.
    Lurie Y; Rouzier-Panis R; Webster GJ; Dusheiko GM; Laughlin M; Jackson ML; Oren R
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):610-5. PubMed ID: 15952104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.
    Tong MJ; Blatt LM; Tong LT; Sayadzadeh K; Conrad A
    J Viral Hepat; 1998 Sep; 5(5):323-31. PubMed ID: 9795916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The factors associated with viral relapse after interferon treatment in chronic hepatitis C patients].
    Ma L; Zhao H; Xie Y; Li MH; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Aug; 14(8):565-8. PubMed ID: 16938164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
    Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
    Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy.
    Abbas Z; Hamid S; Tabassum S
    J Gastroenterol Hepatol; 2002 May; 17(5):577-81. PubMed ID: 12084032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):369-74. PubMed ID: 15313671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.